共 50 条
Vaccines for COVID-19: Where do we stand in 2021?
被引:61
|作者:
Sharma, Ketaki
[1
,2
]
Koirala, Archana
[1
,2
,3
]
Nicolopoulos, Katrina
[1
]
Chiu, Clayton
[1
,2
]
Wood, Nicholas
[1
,2
]
Britton, Philip N.
[2
,4
]
机构:
[1] Natl Ctr Immunisat Res & Surveillance, Westmead, NSW, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[3] Nepean Hosp, Dept Infect Dis, Penrith, NSW, Australia
[4] Childrens Hosp Westmead, Dept Infect Dis & Microbiol, Westmead, NSW, Australia
关键词:
COVID-19;
SARS-CoV-2;
Vaccines;
vaccines;
NCOV-19;
AZD1222;
VACCINE;
EFFICACY;
BNT162B2;
SCOTLAND;
RISK;
D O I:
10.1016/j.prrv.2021.07.001
中图分类号:
R72 [儿科学];
学科分类号:
100202 ;
摘要:
As of July 2021, over 3 billion doses of a COVID-19 vaccines have been administered globally, and there are now 19 COVID-19 vaccines approved for use in at least one country. Several of these have been shown to be highly effective both in clinical trials and real-world observational studies, some of which have included special populations of interest. A small number of countries have approved a COVID-19 vaccine for use in adolescents or children. These are laudable achievements, but the global vaccination effort has been challenged by inequitable distribution of vaccines predominantly to high income countries, with only 0.9% of people in low-income countries having received at least one dose of a COVID-19 vaccine. Addressing this inequity is of critical importance and will result in better control of SARS-CoV-2 globally. Other challenges include: the reduced protection from COVID-19 vaccines against some strains of SARSCoV-2, necessitating the development of variant specific vaccines; and uncertainties around the duration of protection from vaccine-induced immunity. Crown Copyright (c) 2021 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:22 / 31
页数:10
相关论文